Mabylon AG Secures CHF 30 Million to Propel MY006 Allergy Program
Mabylon AG Secures CHF 30 Million for MY006 and Pipeline Advancement
Mabylon AG, a pioneer in the development of human-derived antibodies for treating various medical conditions, has successfully raised CHF 30 million (approximately USD 37 million). This funding aims to enhance its clinical-stage candidate, MY006, while also further enriching its early-stage pipeline. The financing includes a combination of equity investment and a convertible loan.
Strategic Investment in Allergy Treatment
The financial backing will enable Mabylon to push forward with MY006, a groundbreaking tri-specific antibody designed to neutralize peanut allergens. The company plans to complete a Phase Ia/b clinical trial by 2027, aiming to provide compelling safety and preliminary efficacy data for this innovative treatment. This is significant as peanut allergies pose a challenging health issue with limited treatment options available.
Expanding Treatment Options Beyond Peanut Allergies
In addition to MY006, the funding will support the development of other promising candidates. Among these is MY010, an innovative multi-specific antibody targeting the birch Bet v 1 allergen and other birch-related tree and fruit allergens. Furthermore, the funds will facilitate the development of MY011, an antibody formulation aimed at alleviating symptoms associated with grass pollen allergies.
Leadership Changes and Future Directions
During a recent shareholders assembly, Dr. Thomas Hecht was appointed to Mabylon’s Board of Directors, succeeding Prof. Adriano Aguzzi. This change is seen as a strategic move to bring fresh insights and direction to the company's leadership.
Perspectives from Leadership
Gottlieb Keller, Chairman of the Board at Mabylon, expressed his optimism regarding the future. “MY006 addresses a critical need in the allergy treatment landscape. This funding will propel us towards clinical proof-of-concept, representing a vital step in our mission to tackle allergies effectively.” He also acknowledged Prof. Aguzzi's contributions and welcomed Dr. Hecht to his new role.
Alcide Barberis, PhD, CEO of Mabylon, shared his enthusiasm about the recent financing success in a tough global funding climate. He viewed this as a strong endorsement of Mabylon’s innovative approach to developing multi-specific antibodies for allergy treatment. The addition of Dr. Hecht to the Board is expected to further strengthen the company's capacity to advance its pipeline.
About Mabylon AG
Mabylon AG is a Swiss biotech firm dedicated to harnessing the therapeutic potential of naturally occurring human antibodies for the treatment of allergies, inflammatory conditions, and neurodegenerative diseases. The company’s unique approach allows it to create antibodies that directly target epitopes relevant to specific diseases, offering a more effective treatment possibility compared to traditional antibody sources.
Contact Information
For further details or inquiries, reach out to:
Alcide Barberis, CEO
Mabylon AG
Wagistrasse 14
8952 Schlieren
Switzerland
Media Inquiries
For any press-related questions, please contact akampion:
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Email: info@akampion.com
Tel: +49 40 88 16 59 64 / +49 30 23 63 27 68
Frequently Asked Questions
What is the main purpose of the CHF 30 million funding?
The funding is primarily aimed at advancing Mabylon’s MY006 program for peanut allergies and strengthening its early-stage pipeline projects.
Who is involved in the recent leadership change at Mabylon AG?
Dr. Thomas Hecht has joined the Board of Directors, replacing Prof. Adriano Aguzzi, signifying a shift in the company's leadership.
What are some key products in Mabylon's pipeline?
Mabylon is developing several innovative treatments, including MY006 for peanut allergies, MY010 targeting birch allergens, and MY011 for grass pollen allergies.
How does Mabylon AG's approach to antibody development differ?
Mabylon focuses on using naturally occurring human antibodies, which have demonstrated superior efficacy compared to conventional antibody development methods.
What insights did the company's leadership provide regarding the funding?
Leadership expressed confidence that the recent financing validates Mabylon’s strategic direction and innovation in treating allergies through multi-specific antibodies.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.